<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294941</url>
  </required_header>
  <id_info>
    <org_study_id>HQ-US-SHUNT-1701</org_study_id>
    <nct_id>NCT03294941</nct_id>
  </id_info>
  <brief_title>The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology</brief_title>
  <official_title>The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HepQuant, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HepQuant, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a
      minimally-invasive test of liver function and physiology which has been designated by the FDA
      as an investigational drug/device combination product.

      Enrollment into one of the 3 Gilead Selonsertib clinical trials (GS-US-416-2124,
      GS-US-384-1943/1944) is required for enrollment into the HepQuant study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HepQuant study is to run parallel to the Gilead clinical trials,GS-US-416-2124 trial of
      Alcoholic Hepatitis, GS-US-384-1943 trial of non-alcoholic steatohepatitis (NASH) fibrosis
      Stage 3 (STELLAR-3), and, GS-US-384-1944 trial of NASH and compensated cirrhosis (STELLAR-4).
      The time points for the HepQuant SHUNT tests coincide with pre-specified time points within
      the Gilead clinical trials. Subjects enrolled in GILEAD's STELLAR and Alcoholic hepatitis
      trials may participate concurrently in this HepQuant sponsored investigational device study
      at participating US sites only (IDEs as listed above) once approved by the applicable
      IRB/IEC.

      The main eligibility criteria for enrollment into the HepQuant study is enrollment into one
      of the three Gilead clinical trials listed above.

      The HepQuant SHUNT Test is minimally-invasive and measures hepatocyte function and inflow to
      the liver from the simultaneous clearances (hepatic filtration rates, HFRs) of cholate from
      systemic and portal circulations. The Test quantifies portal-systemic shunting (SHUNT) and
      generates a liver disease severity index (DSI). DSI is a score from 0 (no disease) to 50
      (terminal illness) that is a composite of both HFRs and correlates with stage of fibrosis,
      presence of varices, especially large varices, and risk for future clinical outcomes. DSI is
      the primary output variable from the HepQuant SHUNT test. The HepQuant SHUNT test potentially
      satisfies the unmet medical need for a minimally-invasive test of global liver function and
      physiology
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline DSI</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>Baseline severity of liver disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in DSI over study period</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>Improvement or worsening of liver disease severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing DSI to other tests of liver disease severity</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>Correlation of DSI with other baseline tests of liver disease severity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>HepQuant SHUNT Liver Diagnostic Kit</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>HepQuant SHUNT Liver Diagnostic Kit</intervention_name>
    <description>Serial testing over 48 weeks</description>
    <arm_group_label>HepQuant SHUNT Liver Diagnostic Kit</arm_group_label>
    <other_name>SHUNT test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The key inclusion criteria for this HepQuant Parallel Study are the inclusion criteria into
        one of the Gilead selonsertib trials (GS-US-416-2124, GS-US-384-1943 or 1944). Once that
        has been met, subjects must:

          -  Be able to ingest liquid by mouth

          -  Have venous access to support a peripheral IV and 6 blood draws

        Exclusion Criteria:

        The key exclusion criteria for this HepQuant Parallel Study are the exclusion criteria for
        one of the Gilead selonsertib trials (GS-US-416-2124, GS-US-384-1943 or 1944). If this has
        been met, the subject is not eligible to participate in HepQuant. If no exclusion criteria
        has been met for the Gilead selonsertib trial, ADDITIONAL exclusions for HepQuant are:

          -  Subject should not have had first dose of selonsertib

          -  Subject cannot take anything by mouth

          -  Subject cannot be hypersensitive to eggs, albumin preparations, any ingredient in the
             formulation, or component of the container

          -  Subject cannot have intercurrent medical or surgical illness (eg: acute MI, acute
             cerebral hemorrhage, sepsis)

          -  subject cannot have had extensive resection of large segments of small intestine
             (short gut)

          -  Subject cannot have severe gastroparesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Herman, RN, BA</last_name>
    <phone>303-923-2210</phone>
    <email>andrea.herman@hepquant.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steve Helmke, PhD</last_name>
    <email>steve.helmke@hepquant.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Sornmayura, RN</last_name>
      <phone>305-243-6681</phone>
      <email>ksornmayura@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Kaylan Bhamidimarri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Gepty</last_name>
      <phone>215-349-8563</phone>
      <email>christine.gepty@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Rajender Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaToya Thomas</last_name>
      <phone>214-947-1288</phone>
      <email>latoyathomas@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Parvez Mantry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mangesh Pagadala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TX Digestive Disease Consultants</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Marie Jones</last_name>
      <phone>214-820-1710</phone>
      <email>anne.jones@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>James Trotter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertha Buan</last_name>
      <phone>210-253-3426</phone>
      <email>bbuan@txliver.com</email>
    </contact>
    <contact_backup>
      <last_name>Toluwalase Okubote</last_name>
      <phone>210-253-3426</phone>
      <email>tokubote@txliver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Naim Alkhouri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fred Poordad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGuire VA Med Cntr</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Meador</last_name>
      <phone>804-675-6407</phone>
      <email>jill.meador@va.gov</email>
    </contact>
    <investigator>
      <last_name>Michael Fuchs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leslie Yost Schomer</last_name>
      <phone>804-828-6314</phone>
      <email>leslie.yostschomer@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Arun Sanyul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washingtion</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Craft</last_name>
      <phone>206-543-0826</phone>
      <email>jcraft@medicine.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Kiran Bambha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

